Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Aurobindo Pharma
  6. News
  7. Summary
    AUROPHARMA   INE406A01037

AUROBINDO PHARMA

(AUROPHARMA)
  Report
Delayed NSE India Stock Exchange  -  03:51 2022-10-04 am EDT
538.70 INR   +0.65%
09/27Aurobindo Receives FDA Approval for Dicloxacillin Sodium Capsules USP, 250mg and 500mg
AQ
09/22US FDA Concludes Inspection of Aurobindo Pharma Arm's Manufacturing Unit in US
MT
08/29Aurobindo Pharma Arm Gets One Observation from US FDA After US Unit Inspection
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Aurobindo Pharma : Newspaper Advertisements

08/12/2022 | 11:53pm EDT

MUMBAI | 13 AUGUST 2022

9

.

<

Kkalpana Industries (India) Limited

CIN: L19202WB1985PLC039431

Regd Office: New BK Market, 16A Shakespeare Sarani, 4th Floor, Room No. 3, Kolkata - 700071

Telephone: 91-033-4064 7843

E-Mail: kolkata@kkalpana.co.in Website: www.kkalpanagroup.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE 1ST QUARTER ENDED 30TH JUNE 2022

Rs. In Lacs (except per share data)

STANDALONE

CONSOLIDATED

Sl

Quarter ended

Year ended

Quarter ended

Year ended

PARTICULARS

No.

30.06.2022

30.06.2021

31.03.2022

30.06.2022

30.06.2021

31.03.2022

(Un-audited)(Un-audited)

(Audited)

(Un-audited)(Un-audited)

(Audited)

1

Total Income from Operations

10770.98

606.16

4016.15

10770.98

606.16

4016.15

2

Net Profit/(Loss) for the period (before Tax, Exceptional and /or

Extraordinary items)

41.17

58.26

287.60

34.74

52.41

261.25

3

Net Profit/(Loss) for the period before Tax, (after Exceptional and /or

Extraordinary items)

41.17

58.26

287.60

34.74

52.41

261.25

4

Net Profit/(Loss) for the period after Tax, (after Exceptional and /or

Extraordinary items)

30.19

1.49

529.93

23.76

-4.36

503.58

5

Total comprehensive income for the period (Comprising profit/(loss) for the

period (after tax) and other comprehensive income (after tax))

30.19

1.49

529.44

23.76

-4.36

503.25

6

Net Profit after Tax and Share of Profit of Subsidiary/ Associate

24.10

-3.41

501.51

7

Equity Share Capital

1881.46

1881.46

1881.46

1881.46

1881.46

1881.46

8

Reserves (excluding Revaluation Reserve) as shown in Audited Balance

Sheet of the previous year

1482.47

1475.96

9 Earnings per share (of Rs. 2/- each) (for continuing and discontinuing operations)

Basic:

0.03

0.00

0.56

0.03

0.00

0.53

Diluted:

0.03

0.00

0.56

0.03

0.00

0.53

Notes:

  1. The above is an extract of the detailed format of Un-audited Financial Results (Standalone & Consolidated) for the 1st quarter ended 30th June 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The full format of the Un-audited Financial Results (Standalone & Consolidated) for the 1st quarter ended 30th June 2022 are available on the website of BSE Ltd at www.bseindia.com & Calcutta Stock Exchange Limited at www.cse-india.com and that of the Company at www. kkalpanagroup.com
  2. The Un-audited Financial Results (Standalone & Consolidated) for the 1st quarter ended 30th June 2022 have been reviewed by the audit committee and have also been approved by the Board of Directors at their respective meeting held on 12th August 2022. The statutory Auditor has given Limited Review Report for the above financial results.
  3. The Group is engaged primarily in the business of different grades of plastic granules which constitute single reporting segment. Accordingly, the company is a single segment company in accordance with "Indian Accounting Standards 108 Operating Segment".".
  4. The Consolidated Results include Results of :-
    1. the company's Wholly Owned Subsidiary Company viz. "Ddev Plastic Ltd."
    2. the company's Wholly Owned foreign Subsidiary Company viz " Kkalpana Plastic Reprocess Industries Middleeast FZE" and
    3. the Associate Company "Kkalpana Plastick Limited" in which the company holds 36.23% of its paid up Equity share capital.
  5. The figures for the corresponding previous period has been regrouped/reclassified wherever necessary, to conform to the current period figures and to give impact of accounting adjustment arising pursuant to the scheme of Demerger which has been approved by the Honorable National Company Law Tribunal ("NCLT"), vide its order dated 4th March 2022 with Appointed Date 1st April 2021 and effective from 01st April 2022 on filing with the Registrar of Companies.

FOR KKALPANA INDUSTRIES (INDIA) LTD

SD/-

NARRINDRA SURANNA

Place : Kolkata

CHAIRMAN & MANAGING DIRECTOR

Date: 12th August, 2022

(DIN 00060127)

Continuous Excellence Through Performance

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India.

Tel: +91 040 23736370 Fax: +91 40 23747340 Email: info@aurobindo.com

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL

RESULTS FOR THE QUARTER ENDED 30.06.2022

(Rs. in millions)

Standalone

Consolidated

Sr.

Quarter

Year ended

Quarter

Quarter

Year ended

Quarter

Pa

culars

ended

ended

ended

ended

No.

30.06.2022

31.03.2022

30.06.2021

30.06.2022

31.03.2022

30.06.2021

Unaudited

Audited

Unaudited

Unaudited

Audited

Unaudited

1

Total income from opera ons (net)

27,869.2

1,12,871.4

28,937.5

62,359.2

2,34,554.9

57,019.8

2

Net Profit / (Loss) for the period

1,700.7

17,121.9

3,350.5

6,789.9

35,007.1

10,177.1

(before Tax and Ex

onal items)

3

Net Profit / (Loss) for the period before

1,700.7

16,374.8

3,350.5

6,789.9

33,727.4

10,177.1

ta

er Ex

onal items)

4

Net Profit / (Loss) for the period a er

1,221.6

14,547.1

2,150.7

5,203.8

26,471.1

7,699.7

ta

er Ex

onal items)

5

Total Comprehensive income for the

1,225.8

14,564.0

2,134.7

6,974.4

29,087.6

10,013.0

period [ Comprising Profit/(Loss)

fo

er tax) and Other

Compr

er tax)]

6

Paid-up equity Share Capital (face value

585.9

585.9

585.9

585.9

585.9

585.9

of Re.1/- each)

7

Other equity (excluding Revalua on

1,70,587.5

2,45,173.9

Reserve) as shown in the Audited

Balance Sheet

8

Other equity (excluding Revalua on

As on March 31, 2022

As on March 31, 2022

Reserve) as shown in the Audited

170,587.5

245,173.9

Balance Sheet of previous year

9

Earnings per share of ₹1/- each

(not annualised)

(annualised)

(not annualised)

(not annualised)

(annualised)

(not annualised)

(a) Basic (in ₹)

2.08

24.83

3.67

8.88

45.19

13.14

(b) Diluted (in ₹)

2.08

24.83

3.67

8.88

45.19

13.14

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchanges' web sites viz. www.bseindia.com, www.nseindia.com and on the Company's web site viz. www.aurobindo.com

By Order of the Board

Aurobindo Pharma Limited

Sd/-

Place : Hyderabad

K. Nithyananda Reddy

Date : August 11, 2022

Vice Chairman & Managing Director

www.aurobindo.com

APOLLO TYRES' REVENUE UP 30% IN THE 1ST QUARTER

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

Million

QUARTER ENDED

YEAR ENDED

S. No. PARTICULARS

30.06.2022 30.06.2021 31.03.2022

(UNAUDITED)(AUDITED)

1

Total income from operations

59,420.02

45,844.71

209,475.78

  • Net profit / (loss) for the period (before tax and

exceptional items)

2,384.58

1,623.03

8,535.82

  • Net profit / (loss) for the period before tax (after

exceptional items)

2,384.58

1,613.57

8,476.74

  • Net profit / (loss) for the period after tax (after exceptional

items)

1,906.81

1,277.88

6,386.00

  • Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and other

comprehensive income (after tax)]

(1,065.74)

3,611.40

5,312.86

6

Paid up equity share capital (equity shares of 1 each)

635.10

635.10

635.10

7

Reserves excluding revaluation reserves

116,855.00

8

Securities premium account

31,317.67

31,317.67

31,317.67

9

Net worth

116,455.58

118,042.71

117,521.32

10

Paid up debt capital

18,173.14

20,712.72

19,671.21

11

Outstanding redeemable preference shares

-

-

-

12

Debt equity ratio (in times)

0.51

0.58

0.53

13 Earnings per share (of 1 each) (not annualised):

Basic ( )

3.00

2.01

10.06

Diluted ( )

3.00

2.01

10.06

14

Capital redemption reserve

44.40

44.40

44.40

15

Debenture redemption reserve

1,039.50

1,039.50

1,039.50

16

Debt service coverage ratio (in times) #

1.08

3.13

1.14

17

Interest service coverage ratio (in times)

5.23

4.82

4.96

# Based on TTM (Trailing Twelve Months)

Notes:

1. The key standalone financial information of the Company is as under:

Million

QUARTER ENDED

YEAR ENDED

PARTICULARS

30.06.2022

30.06.2021

31.03.2022

(UNAUDITED)

(AUDITED)

Total income from operations

44,362.29

32,199.51

146,494.04

Net profit for the period before tax (after exceptional items)

1,363.51

888.86

3,503.52

Net profit for the period after tax (after exceptional items)

1,043.41

679.24

2,610.64

  1. The above is an extract of the detailed format of quarter ended June 30, 2022 financial results filed with the stock exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarter ended June 30, 2022 financial results (Consolidated/Standalone) are available on the stock exchange websites (National Stock Exchange of India Limited (www.nseindia.com) & BSE Limited (www.bseindia.com)) and on the Company's website (www.apollotyres.com).
  2. For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regula- tions, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited (www.nseindia.com) & BSE Limited (www.bseindia.com) and can be accessed on Company's website (www.apollotyres.com).

APOLLO TYRES LTD

For and on behalf of the Board of Directors of

Apollo Tyres Ltd

CIN: L25111KL1972PLC002449

Regd. Office: 3rd Floor, Areekal Mansion, Near Manorama

Junction, Panampilly Nagar, Kochi 682036, Kerala, India

Sd/-

Corporate Office: Apollo House, 7 Institutional Area,

Sector 32, Gurugram 122001, India.

Tel.: +91 484 4012046, Fax: +91 484 4012048

Place: Gurugram

ONKAR KANWAR

Email: investors@apollotyres.com, www.apollotyres.com

Date: August 12, 2022

CHAIRMAN & MANAGING DIRECTOR

13

2022 9

C

. ÄC≤B

^'êqT

ø±

eT+~

..

^'êqT

.

á

n_

.

á

.

eT+~

ùd n#êÃ

^'êqT

25 ì$TcÕ

^'êqT $ì

bÕ≥T

. C

.

=

eTTK´eT+Á‹ ..?

  • e÷J

á

e÷J

.

@sêŒ≥T

n_

.

ñqï

kÕ-

.

n_

sêJHêe÷

.

eTTK´eT+Á‹>±

O+&Ü*‡q

..

.

ÁbÕC

.

ÁbÕC

˙{≤ eTTì-

ÁbÕC

.100

ÁbÕC

.

Á>±eT+˝À

.10

.

sêJHêe÷'√

ñqï

'êqT

bÕ≥T eTs√ 12

.

e∫à ùde

  • XÊK

ñqï

.

.

21q

ôVA+ eT+Á‹

.

bÕ˝≤«sTT

.

:

.

C≤Ø

.

XÊK

ø±C≤

C

.

.

...

B+'√

.

nsTT´+~. B+'√ Ä

.

kÕe÷Á-,

.

....

C

ñqï

á

.

á

qT+∫ á

.

Disclaimer

Aurobindo Pharma Ltd. published this content on 13 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 August 2022 03:52:01 UTC.


© Publicnow 2022
All news about AUROBINDO PHARMA
09/27Aurobindo Receives FDA Approval for Dicloxacillin Sodium Capsules USP, 250mg and 500mg
AQ
09/22US FDA Concludes Inspection of Aurobindo Pharma Arm's Manufacturing Unit in US
MT
08/29Aurobindo Pharma Arm Gets One Observation from US FDA After US Unit Inspection
MT
08/26Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
RE
08/25Novartis to spin off generics business Sandoz next year
RE
08/24Aurobindo Pharma Unit Gets US FDA's Nod for Generic Birth Control Drug
MT
08/19Aurobindo Pharma : Q1FY2023 – Earning call transcript
PU
08/18Aurobindo Pharma Completes Acquisition of Majority Stake in GLS Pharma
MT
08/16Aurobindo Pharma Unit Gets US FDA's Approval for Vasopressin Injection
MT
08/12Aurobindo Pharma : Newspaper Advertisements
PU
More news
Financials
Sales 2023 253 B 3 105 M 3 105 M
Net income 2023 25 763 M 316 M 316 M
Net cash 2023 20 735 M 254 M 254 M
P/E ratio 2023 12,1x
Yield 2023 0,75%
Capitalization 314 B 3 846 M 3 846 M
EV / Sales 2023 1,16x
EV / Sales 2024 1,02x
Nbr of Employees 15 431
Free-Float 50,7%
Chart AUROBINDO PHARMA
Duration : Period :
Aurobindo Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AUROBINDO PHARMA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 31
Last Close Price 535,20 INR
Average target price 682,55 INR
Spread / Average Target 27,5%
EPS Revisions
Managers and Directors
Kambam Nithyananda Reddy Vice Chairman & Managing Director
Santhanam Subramanian Chief Financial Officer
Kannan Ragunathan Non-Executive Chairman
B. Adi Reddy Secretary & Compliance Officer
Avnit Bimal Singh Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
AUROBINDO PHARMA-27.12%3 846
JOHNSON & JOHNSON-4.60%429 082
ELI LILLY AND COMPANY17.06%305 529
ROCHE HOLDING AG-15.04%267 122
PFIZER, INC.-25.25%247 729
ABBVIE INC.2.16%244 563